Canopy Growth (CGC)
(Delayed Data from NSDQ)
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.86 USD
+0.27 (5.88%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $4.86 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Company News for Aug 11, 2020
by Zacks Equity Research
Companies In The News Are: CGC, GOLD, RCL, MAR.
Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 28.57% and 16.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Aug 10: CGC, SDGR & More
by Trina Mukherjee
Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $19.21 in the latest trading session, marking a -0.57% move from the prior day.
Analysts Estimate Canopy Growth Corporation (CGC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $18.60, moving +0.59% from the previous trading session.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $16.47 in the latest trading session, marking a -1.32% move from the prior day.
Canopy Growth Corporation (CGC) Stock Moves -0.22%: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $18.11, marking a -0.22% move from the previous day.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $16.02 in the latest trading session, marking a -1.9% move from the prior day.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $16.47, moving +1.92% from the previous trading session.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $16.59, moving -0.72% from the previous trading session.
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
by Zacks Equity Research
Zacks Market Edge Highlights: Canopy Growth, Aurora Cannabis, Hexo, GW Pharmaceuticals and Zynerba
Is This a Buying Opportunity in the Marijuana Stocks?
by Tracey Ryniec
The marijuana stocks plunged during the coronavirus sell-off. Should investors be taking a second look?
Is the Options Market Predicting a Spike in Canopy Growth (CGC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed the most recent trading day at $17.18, moving +1.72% from the previous trading session.
Is it Time to Buy Cannabis Stocks & ETFs?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -286.67% and -14.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Canopy Growth (CGC) This Earnings Season?
by Zacks Equity Research
Canopy Growth (CGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Canopy Growth (CGC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal fourth quarter.
Canopy Growth (CGC) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions and Medical-Surgical Solutions segments.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $15.08, marking a -1.71% move from the previous day.
Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?
by Sanghamitra Saha
"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.